Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

The histone methyltransferase WHSC1 is regulated by EZH2 and is important for ovarian clear cell carcinoma cell proliferation.

Kojima M, Sone K, Oda K, Hamamoto R, Kaneko S, Oki S, Kukita A, Machino H, Honjoh H, Kawata Y, Kashiyama T, Asada K, Tanikawa M, Mori-Uchino M, Tsuruga T, Nagasaka K, Matsumoto Y, Wada-Hiraike O, Osuga Y, Fujii T.

BMC Cancer. 2019 May 15;19(1):455. doi: 10.1186/s12885-019-5638-9.

2.

Histone methyltransferase SMYD2 selective inhibitor LLY-507 in combination with poly ADP ribose polymerase inhibitor has therapeutic potential against high-grade serous ovarian carcinomas.

Kukita A, Sone K, Oda K, Hamamoto R, Kaneko S, Komatsu M, Wada M, Honjoh H, Kawata Y, Kojima M, Oki S, Sato M, Asada K, Taguchi A, Miyasaka A, Tanikawa M, Nagasaka K, Matsumoto Y, Wada-Hiraike O, Osuga Y, Fujii T.

Biochem Biophys Res Commun. 2019 May 28;513(2):340-346. doi: 10.1016/j.bbrc.2019.03.155. Epub 2019 Apr 4.

PMID:
30955858
3.

The novel prognostic marker, EHMT2, is involved in cell proliferation via HSPD1 regulation in breast cancer.

Kim SK, Kim K, Ryu JW, Ryu TY, Lim JH, Oh JH, Min JK, Jung CR, Hamamoto R, Son MY, Kim DS, Cho HS.

Int J Oncol. 2019 Jan;54(1):65-76. doi: 10.3892/ijo.2018.4608. Epub 2018 Oct 26.

4.

Overexpression of KDM5B/JARID1B is associated with poor prognosis in hepatocellular carcinoma.

Shigekawa Y, Hayami S, Ueno M, Miyamoto A, Suzaki N, Kawai M, Hirono S, Okada KI, Hamamoto R, Yamaue H.

Oncotarget. 2018 Sep 28;9(76):34320-34335. doi: 10.18632/oncotarget.26144. eCollection 2018 Sep 28.

5.

A Positive Correlation Between the EZH2 and PD-L1 Expression in Resected Lung Adenocarcinomas.

Toyokawa G, Takada K, Tagawa T, Hamamoto R, Yamada Y, Shimokawa M, Oda Y, Maehara Y.

Ann Thorac Surg. 2019 Feb;107(2):393-400. doi: 10.1016/j.athoracsur.2018.08.056. Epub 2018 Oct 18.

PMID:
30343006
6.

Prevalence of Enhancer of Zeste Homolog 2 in Patients with Resected Small Cell Lung Cancer.

Toyokawa G, Takada K, Tagawa T, Kinoshita F, Kozuma Y, Matsubara T, Haratake N, Takamori S, Akamine T, Hirai F, Yamada Y, Hamamoto R, Oda Y, Maehara Y.

Anticancer Res. 2018 Jun;38(6):3707-3711. doi: 10.21873/anticanres.12649.

PMID:
29848731
7.

Clinical Value of Serum p53 Antibody in the Diagnosis and Prognosis of Esophageal Squamous Cell Carcinoma.

Kunizaki M, Hamasaki K, Wakata K, Tobinaga S, Sumida Y, Hidaka S, Yasutake T, Miyazaki T, Matsumoto K, Yamasaki T, Sawai T, Hamamoto R, Nanashima A, Nagayasu T.

Anticancer Res. 2018 Mar;38(3):1807-1813.

PMID:
29491120
8.

Clinical significance of the C-reactive protein-to-albumin ratio for the prognosis of patients with esophageal squamous cell carcinoma.

Kunizaki M, Tominaga T, Wakata K, Miyazaki T, Matsumoto K, Sumida Y, Hidaka S, Yamasaki T, Yasutake T, Sawai T, Hamamoto R, Nanashima A, Nagayasu T.

Mol Clin Oncol. 2018 Feb;8(2):370-374. doi: 10.3892/mco.2017.1527. Epub 2017 Dec 8.

9.

Novel prognostic marker PRMT1 regulates cell growth via downregulation of CDKN1A in HCC.

Ryu JW, Kim SK, Son MY, Jeon SJ, Oh JH, Lim JH, Cho S, Jung CR, Hamamoto R, Kim DS, Cho HS.

Oncotarget. 2017 Dec 14;8(70):115444-115455. doi: 10.18632/oncotarget.23296. eCollection 2017 Dec 29.

10.

Interactions between protein molecules and the virus removal membrane surface: Effects of immunoglobulin G adsorption and conformational changes on filter performance.

Hamamoto R, Ito H, Hirohara M, Chang R, Hongo-Hirasaki T, Hayashi T.

Biotechnol Prog. 2018 Mar;34(2):379-386. doi: 10.1002/btpr.2586. Epub 2017 Dec 11.

PMID:
29193824
11.

Regulation of poly(ADP-Ribose) polymerase 1 functions by post-translational modifications.

Piao L, Fujioka K, Nakakido M, Hamamoto R.

Front Biosci (Landmark Ed). 2018 Jan 1;23:13-26. Review.

PMID:
28930534
12.

Critical roles of SMYD2-mediated β-catenin methylation for nuclear translocation and activation of Wnt signaling.

Deng X, Hamamoto R, Vougiouklakis T, Wang R, Yoshioka Y, Suzuki T, Dohmae N, Matsuo Y, Park JH, Nakamura Y.

Oncotarget. 2017 Jul 27;8(34):55837-55847. doi: 10.18632/oncotarget.19646. eCollection 2017 Aug 22.

13.

Protein lysine methyltransferase SMYD3 is involved in tumorigenesis through regulation of HER2 homodimerization.

Yoshioka Y, Suzuki T, Matsuo Y, Tsurita G, Watanabe T, Dohmae N, Nakamura Y, Hamamoto R.

Cancer Med. 2017 Jul;6(7):1665-1672. doi: 10.1002/cam4.1099. Epub 2017 Jun 22.

14.

Oncogenic histone methyltransferase EZH2: A novel prognostic marker with therapeutic potential in endometrial cancer.

Oki S, Sone K, Oda K, Hamamoto R, Ikemura M, Maeda D, Takeuchi M, Tanikawa M, Mori-Uchino M, Nagasaka K, Miyasaka A, Kashiyama T, Ikeda Y, Arimoto T, Kuramoto H, Wada-Hiraike O, Kawana K, Fukayama M, Osuga Y, Fujii T.

Oncotarget. 2017 Jun 20;8(25):40402-40411. doi: 10.18632/oncotarget.16316.

15.

Clinical Significance of Serum p53 Antibody in the Early Detection and Poor Prognosis of Gastric Cancer.

Kunizaki M, Fukuda A, Wakata K, Tominaga T, Nonaka T, Miyazaki T, Matsumoto K, Sumida Y, Hidaka S, Yasutake T, Sawai T, Hamamoto R, Nanashima A, Nagayasu T.

Anticancer Res. 2017 Apr;37(4):1979-1984.

PMID:
28373470
16.

Effects of SMYD2-mediated EML4-ALK methylation on the signaling pathway and growth in non-small-cell lung cancer cells.

Wang R, Deng X, Yoshioka Y, Vougiouklakis T, Park JH, Suzuki T, Dohmae N, Ueda K, Hamamoto R, Nakamura Y.

Cancer Sci. 2017 Jun;108(6):1203-1209. doi: 10.1111/cas.13245.

17.

Elevated Metabolic Activity on 18F-FDG PET/CT Is Associated with the Expression of EZH2 in Non-small Cell Lung Cancer.

Toyokawa G, Takada K, Okamoto T, Kozuma Y, Matsubara T, Haratake N, Akamine T, Takamori S, Katsura M, Shoji F, Hamamoto R, Oda Y, Maehara Y.

Anticancer Res. 2017 Mar;37(3):1393-1401.

PMID:
28314309
18.

Loss of BRCA1 in the Cells of Origin of Ovarian Cancer Induces Glycolysis: A Window of Opportunity for Ovarian Cancer Chemoprevention.

Chiyoda T, Hart PC, Eckert MA, McGregor SM, Lastra RR, Hamamoto R, Nakamura Y, Yamada SD, Olopade OI, Lengyel E, Romero IL.

Cancer Prev Res (Phila). 2017 Apr;10(4):255-266. doi: 10.1158/1940-6207.CAPR-16-0281. Epub 2017 Mar 6.

19.

WHSC1L1-mediated EGFR mono-methylation enhances the cytoplasmic and nuclear oncogenic activity of EGFR in head and neck cancer.

Saloura V, Vougiouklakis T, Zewde M, Deng X, Kiyotani K, Park JH, Matsuo Y, Lingen M, Suzuki T, Dohmae N, Hamamoto R, Nakamura Y.

Sci Rep. 2017 Jan 19;7:40664. doi: 10.1038/srep40664.

20.

Longitudinal Prediction of Suicide Attempts for a Diverse Adolescent Sample of Native Hawaiians, Pacific Peoples, and Asian Americans.

Hishinuma ES, Smith MD, McCarthy K, Lee M, Goebert DA, Sugimoto-Matsuda JJ, Andrade NN, Philip JB, Chung-Do JJ, Hamamoto RS, Andrade JKL.

Arch Suicide Res. 2018 Jan-Mar;22(1):67-90. doi: 10.1080/13811118.2016.1275992. Epub 2017 Feb 3.

PMID:
28071982
21.

Functional Genomics, Genetics, and Bioinformatics 2016.

Deng Y, Wang H, Hamamoto R, Duan S, Pirooznia M, Bai Y.

Biomed Res Int. 2016;2016:2625831. Epub 2016 Nov 22. No abstract available.

22.

The Prognostic Impact of Jumonji Domain-containing 2B in Patients with Resected Lung Adenocarcinoma.

Toyokawa G, Taguchi K, Edagawa M, Shimamatsu S, Toyozawa R, Nosaki K, Hirai F, Yamaguchi M, Shimokawa M, Seto T, Takenoyama M, Hamamoto R, Sugio K, Ichinose Y.

Anticancer Res. 2016 Sep;36(9):4841-6.

PMID:
27630338
23.

SMYD3-mediated lysine methylation in the PH domain is critical for activation of AKT1.

Yoshioka Y, Suzuki T, Matsuo Y, Nakakido M, Tsurita G, Simone C, Watanabe T, Dohmae N, Nakamura Y, Hamamoto R.

Oncotarget. 2016 Nov 15;7(46):75023-75037. doi: 10.18632/oncotarget.11898.

24.

Clinical Value of Serum p53 Antibody in the Diagnosis and Prognosis of Colorectal Cancer.

Kunizaki M, Sawai T, Takeshita H, Tominaga T, Hidaka S, To K, Miyazaki T, Hamamoto R, Nanashima A, Nagayasu T.

Anticancer Res. 2016 Aug;36(8):4171-5.

PMID:
27466527
25.

WHSC1L1 drives cell cycle progression through transcriptional regulation of CDC6 and CDK2 in squamous cell carcinoma of the head and neck.

Saloura V, Vougiouklakis T, Zewde M, Kiyotani K, Park JH, Gao G, Karrison T, Lingen M, Nakamura Y, Hamamoto R.

Oncotarget. 2016 Jul 5;7(27):42527-42538. doi: 10.18632/oncotarget.9897.

26.

Automethylation of SUV39H2, an oncogenic histone lysine methyltransferase, regulates its binding affinity to substrate proteins.

Piao L, Nakakido M, Suzuki T, Dohmae N, Nakamura Y, Hamamoto R.

Oncotarget. 2016 Apr 19;7(16):22846-56. doi: 10.18632/oncotarget.8072.

27.

Dysregulation of protein methyltransferases in human cancer: An emerging target class for anticancer therapy.

Hamamoto R, Nakamura Y.

Cancer Sci. 2016 Apr;107(4):377-84. doi: 10.1111/cas.12884. Epub 2016 Feb 9. Review.

28.

SUV420H1 enhances the phosphorylation and transcription of ERK1 in cancer cells.

Vougiouklakis T, Sone K, Saloura V, Cho HS, Suzuki T, Dohmae N, Alachkar H, Nakamura Y, Hamamoto R.

Oncotarget. 2015 Dec 22;6(41):43162-71. doi: 10.18632/oncotarget.6351.

29.

Targeting Suppressor of Variegation 3-9 Homologue 2 (SUV39H2) in Acute Lymphoblastic Leukemia (ALL).

Mutonga M, Tamura K, Malnassy G, Fulton N, de Albuquerque A, Hamamoto R, Stock W, Nakamura Y, Alachkar H.

Transl Oncol. 2015 Oct;8(5):368-75. doi: 10.1016/j.tranon.2015.07.003.

30.

PRMT1 promotes mitosis of cancer cells through arginine methylation of INCENP.

Deng X, Von Keudell G, Suzuki T, Dohmae N, Nakakido M, Piao L, Yoshioka Y, Nakamura Y, Hamamoto R.

Oncotarget. 2015 Nov 3;6(34):35173-82. doi: 10.18632/oncotarget.6050.

31.

The LSD1 Family of Histone Demethylases and the Pumilio Posttranscriptional Repressor Function in a Complex Regulatory Feedback Loop.

Miles WO, Lepesant JM, Bourdeaux J, Texier M, Kerenyi MA, Nakakido M, Hamamoto R, Orkin SH, Dyson NJ, Di Stefano L.

Mol Cell Biol. 2015 Dec;35(24):4199-211. doi: 10.1128/MCB.00755-15. Epub 2015 Oct 5.

32.

PRMT6 increases cytoplasmic localization of p21CDKN1A in cancer cells through arginine methylation and makes more resistant to cytotoxic agents.

Nakakido M, Deng Z, Suzuki T, Dohmae N, Nakamura Y, Hamamoto R.

Oncotarget. 2015 Oct 13;6(31):30957-67. doi: 10.18632/oncotarget.5143.

33.

SUV39H2 methylates and stabilizes LSD1 by inhibiting polyubiquitination in human cancer cells.

Piao L, Suzuki T, Dohmae N, Nakamura Y, Hamamoto R.

Oncotarget. 2015 Jul 10;6(19):16939-50.

34.

Functional genomics, genetics, and bioinformatics.

Deng Y, Wang H, Hamamoto R, Schaffer D, Duan S.

Biomed Res Int. 2015;2015:184824. doi: 10.1155/2015/184824. Epub 2015 Apr 22. No abstract available.

35.

The NSD family of protein methyltransferases in human cancer.

Vougiouklakis T, Hamamoto R, Nakamura Y, Saloura V.

Epigenomics. 2015 Aug;7(5):863-74. doi: 10.2217/epi.15.32. Epub 2015 May 5. Review.

PMID:
25942451
36.

Dysregulation of AKT Pathway by SMYD2-Mediated Lysine Methylation on PTEN.

Nakakido M, Deng Z, Suzuki T, Dohmae N, Nakamura Y, Hamamoto R.

Neoplasia. 2015 Apr;17(4):367-73. doi: 10.1016/j.neo.2015.03.002.

37.

Critical roles of non-histone protein lysine methylation in human tumorigenesis.

Hamamoto R, Saloura V, Nakamura Y.

Nat Rev Cancer. 2015 Feb;15(2):110-24. doi: 10.1038/nrc3884. Review.

PMID:
25614009
38.

Critical role of lysine 134 methylation on histone H2AX for γ-H2AX production and DNA repair.

Sone K, Piao L, Nakakido M, Ueda K, Jenuwein T, Nakamura Y, Hamamoto R.

Nat Commun. 2014 Dec 9;5:5691. doi: 10.1038/ncomms6691.

39.

WHSC1 promotes oncogenesis through regulation of NIMA-related kinase-7 in squamous cell carcinoma of the head and neck.

Saloura V, Cho HS, Kiyotani K, Alachkar H, Zuo Z, Nakakido M, Tsunoda T, Seiwert T, Lingen M, Licht J, Nakamura Y, Hamamoto R.

Mol Cancer Res. 2015 Feb;13(2):293-304. doi: 10.1158/1541-7786.MCR-14-0292-T. Epub 2014 Oct 3.

40.

Late Cornified Envelope Group I, a novel target of p53, regulates PRMT5 activity.

Deng Z, Matsuda K, Tanikawa C, Lin J, Furukawa Y, Hamamoto R, Nakamura Y.

Neoplasia. 2014 Aug;16(8):656-64. doi: 10.1016/j.neo.2014.07.008.

41.

SMYD2-dependent HSP90 methylation promotes cancer cell proliferation by regulating the chaperone complex formation.

Hamamoto R, Toyokawa G, Nakakido M, Ueda K, Nakamura Y.

Cancer Lett. 2014 Aug 28;351(1):126-33. doi: 10.1016/j.canlet.2014.05.014. Epub 2014 May 28.

PMID:
24880080
42.

The histone methyltransferase SMYD2 methylates PARP1 and promotes poly(ADP-ribosyl)ation activity in cancer cells.

Piao L, Kang D, Suzuki T, Masuda A, Dohmae N, Nakamura Y, Hamamoto R.

Neoplasia. 2014 Mar;16(3):257-64, 264.e2. doi: 10.1016/j.neo.2014.03.002. Epub 2014 Apr 13.

43.

The oncogenic polycomb histone methyltransferase EZH2 methylates lysine 120 on histone H2B and competes ubiquitination.

Kogure M, Takawa M, Saloura V, Sone K, Piao L, Ueda K, Ibrahim R, Tsunoda T, Sugiyama M, Atomi Y, Nakamura Y, Hamamoto R.

Neoplasia. 2013 Nov;15(11):1251-61.

44.

Deregulation of the histone demethylase JMJD2A is involved in human carcinogenesis through regulation of the G(1)/S transition.

Kogure M, Takawa M, Cho HS, Toyokawa G, Hayashi K, Tsunoda T, Kobayashi T, Daigo Y, Sugiyama M, Atomi Y, Nakamura Y, Hamamoto R.

Cancer Lett. 2013 Aug 9;336(1):76-84. doi: 10.1016/j.canlet.2013.04.009. Epub 2013 Apr 18.

PMID:
23603248
45.

Lysyl 5-hydroxylation, a novel histone modification, by Jumonji domain containing 6 (JMJD6).

Unoki M, Masuda A, Dohmae N, Arita K, Yoshimatsu M, Iwai Y, Fukui Y, Ueda K, Hamamoto R, Shirakawa M, Sasaki H, Nakamura Y.

J Biol Chem. 2013 Mar 1;288(9):6053-62. doi: 10.1074/jbc.M112.433284. Epub 2013 Jan 9.

46.

The histone methyltransferase Wolf-Hirschhorn syndrome candidate 1-like 1 (WHSC1L1) is involved in human carcinogenesis.

Kang D, Cho HS, Toyokawa G, Kogure M, Yamane Y, Iwai Y, Hayami S, Tsunoda T, Field HI, Matsuda K, Neal DE, Ponder BA, Maehara Y, Nakamura Y, Hamamoto R.

Genes Chromosomes Cancer. 2013 Feb;52(2):126-39. doi: 10.1002/gcc.22012. Epub 2012 Sep 25.

PMID:
23011637
47.

Enhanced HSP70 lysine methylation promotes proliferation of cancer cells through activation of Aurora kinase B.

Cho HS, Shimazu T, Toyokawa G, Daigo Y, Maehara Y, Hayami S, Ito A, Masuda K, Ikawa N, Field HI, Tsuchiya E, Ohnuma S, Ponder BA, Yoshida M, Nakamura Y, Hamamoto R.

Nat Commun. 2012;3:1072. doi: 10.1038/ncomms2074.

48.

Recognition of modification status on a histone H3 tail by linked histone reader modules of the epigenetic regulator UHRF1.

Arita K, Isogai S, Oda T, Unoki M, Sugita K, Sekiyama N, Kuwata K, Hamamoto R, Tochio H, Sato M, Ariyoshi M, Shirakawa M.

Proc Natl Acad Sci U S A. 2012 Aug 7;109(32):12950-5. doi: 10.1073/pnas.1203701109. Epub 2012 Jul 25.

49.

RB1 methylation by SMYD2 enhances cell cycle progression through an increase of RB1 phosphorylation.

Cho HS, Hayami S, Toyokawa G, Maejima K, Yamane Y, Suzuki T, Dohmae N, Kogure M, Kang D, Neal DE, Ponder BA, Yamaue H, Nakamura Y, Hamamoto R.

Neoplasia. 2012 Jun;14(6):476-86.

50.

Histone lysine methyltransferase SETD8 promotes carcinogenesis by deregulating PCNA expression.

Takawa M, Cho HS, Hayami S, Toyokawa G, Kogure M, Yamane Y, Iwai Y, Maejima K, Ueda K, Masuda A, Dohmae N, Field HI, Tsunoda T, Kobayashi T, Akasu T, Sugiyama M, Ohnuma S, Atomi Y, Ponder BA, Nakamura Y, Hamamoto R.

Cancer Res. 2012 Jul 1;72(13):3217-27. doi: 10.1158/0008-5472.CAN-11-3701. Epub 2012 May 3.

Supplemental Content

Loading ...
Support Center